The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models

URN to cite this document:: urn:nbn:de:bvb:355-epub-415481
DOI to cite this document:: 10.5283/epub.41548

Ribback, Silvia ; Sailer, V. ; Böhning, E. ; Utpatel, Kirsten ; Evert, Matthias

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(11MB)

Date of publication of this fulltext: 11 Feb 2020 11:17

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Activation of the epidermal growth factor receptor (EGFR) signaling pathway promotes the development of hepatocellular adenoma (HCA) and carcinoma (HCC). The selective EGFR inhibitor Gefitinib was found to prevent hepatocarcinogenesis in rat cirrhotic livers. Thus, Gefitinib might reduce progression of pre-neoplastic liver lesions to HCC. In short-and long-term experiments, administration of ...